PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals, Inc.'s quarterly additional paid-in capital increased from Jun. 2013 ($541.76 Mil) to Sep. 2013 ($547.87 Mil) and increased from Sep. 2013 ($547.87 Mil) to Dec. 2013 ($548.51 Mil).
Progenics Pharmaceuticals, Inc.'s annual additional paid-in capital increased from Dec. 2011 ($463.44 Mil) to Dec. 2012 ($493.61 Mil) and increased from Dec. 2012 ($493.61 Mil) to Dec. 2013 ($548.51 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Progenics Pharmaceuticals, Inc. Annual Data
Progenics Pharmaceuticals, Inc. Quarterly Data